Zobrazeno 1 - 10
of 118
pro vyhledávání: '"H. Portengen"'
Autor:
Alexander Olek, John A. Foekens, Maxime P. Look, Fabian Model, Antje Kluth, Marion E. Meijer-van Gelder, Heinz Höfler, Marion Kiechle, Joan Bolt-de Vries, Jan G. M. Klijn, John W.M. Martens, Nadia Harbeck, Anieta M. Sieuwerts, Manfred Schmitt, Sabine Maier, Inko Nimmrich, Christian Piepenbrock, Thomas Koenig, H. Portengen
Publikováno v:
Cancer Research, 65(10), 4101-4107. American Association for Cancer Research Inc.
To understand the biological basis of resistance to endocrine therapy is of utmost importance in patients with steroid hormone receptor–positive breast cancer. Not only will this allow us prediction of therapy success, it may also lead to novel the
Autor:
D. de Jong, Jan G. M. Klijn, H. Portengen, Doorléne T. H. van Tienoven, Fred C. G. J. Sweep, Simone P. J. van Broekhoven, Lambert C. J. Dorssers, Nicolai Grebenchtchikov, Paul N. Span, H. A. Peters, Arend Brinkman, Marion E. Meijer-van Gelder, John A. Foekens, Anneke Geurts-Moespot, Maxime P. Look
Publikováno v:
Clinical Cancer Research, 10, 18 Pt 1, pp. 6194-202
Clinical Cancer Research, 10, 6194-6202. American Association for Cancer Research Inc.
Clinical Cancer Research, 10, 6194-202
Clinical Cancer Research, 10, 6194-6202. American Association for Cancer Research Inc.
Clinical Cancer Research, 10, 6194-202
Purpose: BCAR1, the human homologue of the rat p130Cas protein, was identified in a functional screen for human breast cancer cell proliferation resistant to antiestrogen drugs. Here, we study the prognostic value of quantitative BCAR1 levels in a la
Autor:
M.E. Meijer-van Gelder, Lambert C. J. Dorssers, H. Portengen, Hanne Meijers-Heijboer, I. L. Van Staveren, J.A. Foekens, L Verhoog, Emjj Berns, J.G.M. Klijn, A M W van de Ouweland
Publikováno v:
British Journal of Cancer
British journal of cancer, 85(4), 538-545. Nature Publishing Group
British Journal of Cancer, 85(4), 538-545. Nature Publishing Group
British journal of cancer, 85(4), 538-545. Nature Publishing Group
British Journal of Cancer, 85(4), 538-545. Nature Publishing Group
About 5–10% of breast cancers are hereditary; a genetically and clinically heterogeneous disease in which several susceptibility genes, including BRCA1, have been identified. While distinct tumour features can be used to estimate the likelihood tha
Autor:
J.G.M. Klijn, J.A. Foekens, W. L. J. Van Putten, H. Portengen, J. Alexieva-Figusch, Maxime P. Look
Publikováno v:
Breast Cancer Research and Treatment. 29:73-83
In a study on 214 patients with primary breast cancer (median follow-up 8.5 yr, maximum follow-up 15 yr), EGF-R was negatively correlated to estrogen receptor and progesterone receptor, whereas no association was found with age, lymph node status, an
Autor:
H. Y. W. C. M. De Koning, W. L. J. Van Putten, B. Thirion, J.G.M. Klijn, H. Portengen, J.A. Foekens, J. Alexieva-Figusch
Publikováno v:
Journal of Clinical Oncology. 11:899-908
PURPOSE Evaluation of the prognostic value of cytosolic PS2 (pS2 protein) and cathepsin D in a large series of breast cancer patients by multivariate analysis taking into account steroid receptors and conventional prognostic factors. PATIENTS AND MET
Autor:
Jan G. M. Klijn, W.C.H. de Koning, H. Portengen, W. L. J. Van Putten, J.A. Foekens, Emjj Berns, I. L. Van Staveren
Publikováno v:
The Journal of Steroid Biochemistry and Molecular Biology. 43:13-19
Amplification of oncogenes in primary tumours may have prognostic and/or therapeutic significance for patients with breast cancer. We have studied HER2/neu and c-myc amplification together with steroid receptors in human primary breast tumours and re
Autor:
Iris L. van Staveren, Els M.J.J. Berns, Jan G. M. Klijn, Erica Noordegraaf, H. Portengen, John A. Foekens
Publikováno v:
European Journal of Cancer. 28:697-700
The frequency of oncogene amplification described in the literature shows a large fluctuation, which could be attributed to the study of relatively small series of tumours, to selection of subgroups of patients, or, especially in retrospective studie
Autor:
J.G.M. Klijn, S. W. J. Lamberts, G.H. Bakker, W. L. J. Van Putten, B. Setyono-Han, J.A. Foekens, H. Portengen, F. H. De Jong, Jean Claude Reubi
Publikováno v:
Breast Cancer Research and Treatment. 17:23-32
The effects of treatment with a somatostatin analog (Sandostatin, SMS201-995) were investigated in female rats with dimethylbenzanthracene (DMBA)-induced rat mammary tumors. A 3-week treatment was performed using sandostatin, the LHRH-agonist buserel
Autor:
Jgm Klijn, Theo Kok, Am M. Hoff, Ja A. Foekens, Jaap Verweij, A. S. T. Planting, Swj W. Lamberts, H. Portengen
Publikováno v:
British Journal of Cancer
Somatostatin analogues can suppress the secretion of some gastrointestinal hormones and growth factors involved in the growth regulation of gastrointestinal cancers and can inhibit the growth of experimental pancreatic tumours. Therefore, in a phase
Autor:
Marion E. Meijer-van Gelder, John A. Foekens, Thomas Koenig, Dimo Dietrich, Joan Bolt-de Vries, Ina Schwope, Antje Kluth, Maxime P. Look, Jan G. M. Klijn, John W.M. Martens, Manfred Schmitt, Anieta M. Sieuwerts, Oliver Hartmann, H. Portengen, Viktor Magdolen, Ralf Lesche, Sabine Maier, Inko Nimmrich, Nadia Harbeck
Publikováno v:
Breast Cancer Research and Treatment, 111(3), 429-437. Springer New York
Background In this study, we evaluated if PITX2 DNA methylation is a marker for disease recurrence in lymph node-negative (LNN), steroid hormone receptor-positive (HR+) breast cancer patients. In addition, we studied the association between PITX2 DNA